UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 8, 2015

CORMEDIX INC. (Exact Name of Registrant as Specified in Charter)

Delaware	001-34673	20-5894890
(State or Other		
Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)
1430 US Highway 206, Suite 200, Bedminster, NJ		07921

(Address of Principal Executive Offices)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Zip Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

" Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

" Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

" Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

CorMedix Inc. will provide an update on its patent infringement case and utility model claims in Germany during its investor conference call at 9:00 a.m. today, May 8, 2015. In order to participate in the conference call, please call 1-877-407-8031 (U.S.), 1-201-689-8031 (outside the U.S.). All participants who dial in will need to give the operator first and last name, company name and phone number. Reference: CorMedix. A replay of this call will be available at (U.S.):1-877-660-6853 (International): 1-201-612-7415 Conference ID #: 13609469.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: May 8, 2015

By:

/s/ Randy Milby Name: Randy Milby Title: Chief Executive Officer

3